Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib

ABSTRACT: Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and geffitinib. However, nearly all patients show relapse within 1 year after initial treatment. We used microarrays to detail global gene expression changes in EGFR mutant cells vs. WT cells responding to erlotinib. 4 EGFR mutant and 4 WT NSCLC cells were treated with or without erlotinib for 24 hr, followed by RNA extraction and hybridization on Affymetrix microarrays.

ORGANISM(S): Homo sapiens

SUBMITTER: Lee Ho-June 

PROVIDER: S-ECPF-GEOD-57156 | biostudies-other |

REPOSITORIES: biostudies-other